bioAffinity Technologies reported Q1 2024 revenue of $2.406 million, marking a notable sequential increase from the prior period and a reported YoY uplift driven by a low base in the prior year. Gross profit was $683 thousand, delivering a gross margin of 28.4%. However, the quarter generated an operating loss of $1.945 million and a net loss of $1.962 million, resulting in an EPS of -0.20. EBITDA was negative at -$1.785 million, with an EBITDAR of -0.742 and an operating cash burn of $2.345 million. The company ended the quarter with cash of about $2.45 million and total debt of approximately $1.494 million, producing a net debt position of roughly -$0.96 million. Adding financing activities helped offset some cash burn, but the quarter underscores a continuing need for external funding to sustain operations and drive product commercialization.
Key driver of the narrative remains bioAffinity’s CyPath lung product and related R&D investments. Management commentary (not provided in the data) would typically address milestones for validation, payer acceptance, and potential partnerships to scale revenue. Given the strong cash utilization and lack of GAAP profitability, the near-term investment thesis hinges on achieving meaningful adoption of CyPath lung, reducing per-unit costs, and securing additional funding or strategic collaborations to extend the operating runway. Investors should monitor the cadence of product validation, reimbursement progress, and any strategic financing announcements as a prerequisite for meaningful multiple expansion or margin improvement.